Prognostic Value of Cardiac Sympathetic Nerve Activity Evaluated by 123I-Metaiodobenzylguanidine Imaging in Patients with ST-Segment Elevation Myocardial Infarction

Prognostic Value of Cardiac Sympathetic Nerve Activity Evaluated by 123I-Metaiodobenzylguanidine Imaging in Patients with ST-Segment Elevation Myocardial Infarction - Prognostic Value of 123I-MIBG in STEMI

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001380

Enrollment

200

Registered

2008-09-17

Start date

2000-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment elevation myocardial infarction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Made on the basis of chest pain of > 30 min duration 2) ST-segment elevation of > 2 mm in two electrocardiographic (ECG) leads 3) More than threefold increase in serum creatine phosphokinase (CPK) activities 4)Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) Hepatic failure 2) Svere renal failure 3) Active cancer 4) Severe heart failure requiring mechanical support (mechanical ventilation, intraaortic balloon pumping, left ventricular assist device, or cardiac resynchronization therapy) 5) Requiring heart transplantation

Design outcomes

Primary

Measure	Time frame
Major adverse cardiac events	—

Countries

Japan

Contacts

Public ContactShu Kasama

Kitakanto Cardiovascular Hospital Internal Medicine

s-kasama@bay.wind.ne.jp027(232)7111

Outcome results